

BOSTON SCIENTIFIC CORP  
Form 8-K  
March 06, 2007

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): March 1, 2007

**BOSTON SCIENTIFIC CORPORATION**  
(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other  
jurisdiction of  
incorporation)

**1-11083**  
(Commission  
file number)

**04-2695240**  
(IRS employer  
identification no.)

**One Boston Scientific Place, Natick, Massachusetts**  
(Address of principal executive offices)

**01760-1537**  
(Zip code)

Registrant's telephone number, including area code: **(508) 650-8000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**ITEM 7.01.**

**REGULATION FD DISCLOSURE.**

On March 5, 2007, Boston Scientific Corporation (the “Company”) issued a press release announcing a request for information received on March 1, 2007, from Representative Henry A. Waxman, Chairman of the Committee on Oversight and Government Reform of the U.S. House of Representatives, about the Company’s TAXUS® paclitaxel-eluting coronary stents. A copy of the press release is furnished with this report as Exhibit 99.1. A form of the request letter is furnished with this report as Exhibit 99.2.

*The information in this Current Report on Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.*

**ITEM 9.01.**

**FINANCIAL STATEMENTS AND EXHIBITS.**

**Exhibit No.**

**Description**

- |      |   |
|------|---|
| 99.1 | Press Release issued by Boston Scientific Corporation dated March 5, 2007.                    |
| 99.2 | Form of Letter from the Committee on Oversight and Government Reform dated February 28, 2007. |

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BOSTON SCIENTIFIC CORPORATION**

Date: March 6, 2007

By: /s/ Lawrence J. Knopf

\_\_\_\_\_  
Lawrence J. Knopf  
Vice President and Assistant General Counsel

**INDEX TO EXHIBITS**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release issued by Boston Scientific Corporation dated March 5, 2007.
99.2	Form of Letter from the Committee on Oversight and Government Reform dated February 28, 2007.

-4-

---